Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer
Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer
Not yet recruiting · NCT07552181 · Registry updated 2026-08-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Not yet recruiting | Phase 2 | 2026-08-05 | NCT07552181 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Miyarisan Pharmaceuticals, Co., Ltd. | 2 |
| Osel, Inc. | 3 |
| Yuan Yuan | 2 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cedars-Sinai Medical Center Beverly Hills | Beverly Hills | United States | 1 |
| CS Cancer at Valley Oncology Medical Group | Tarzana | United States | 3 |
| Hunt Cancer Institute, an Affiliate of CS Cancer | Torrance | United States | 2 |